<DOC>
	<DOCNO>NCT01195272</DOCNO>
	<brief_summary>This open-label , single arm study assess effect RoActemra/Actemra ( tocilizumab ) neutrophils monitor safety benefit-risk RoActemra/Actemra treatment patient active rheumatoid arthritis inadequate response current biologic non-biologic disease-modifying antirheumatic drug ( DMARDs ) . Patients receive RoActemra/Actemra dose 8 mg/kg intravenously every 4 week , either monotherapy combination current non-biologic DMARD . Anticipated time study treatment 52 week .</brief_summary>
	<brief_title>A Study Effects RoActemra/Actemra ( Tocilizumab ) Neutrophils Patients With Active Rheumatoid Arthritis Who Have Inadequate Response Biologic and/or Non-biologic DMARDs .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Moderate severe active rheumatoid arthritis &gt; /= 6 month duration DAS28 &gt; /= 3.2 screen baseline Inadequate response biologic nonbiologic DMARDs Biologic DMARDs must withdraw ( approximately 5 halflives agent ) first dose study drug If continue nonbiologic DMARD , dose stable least 8 week Oral corticosteroid must stable dose least 25 28 day prior baseline Major surgery ( include joint surgery ) within 8 week prior screen recover prior surgery Rheumatic autoimmune disease RA Functional class IV define American College Rheumatology ( ACR ) classification Prior history current inflammatory joint disease RA Previous treatment celldepleting therapy Intraarticular parenteral corticosteroid within 4 week prior baseline Active infection history recurrent infection Positive HIV hepatitis B C History current primary secondary immunodeficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>